CN1229331C - 一元胺吸收的抑制剂 - Google Patents

一元胺吸收的抑制剂 Download PDF

Info

Publication number
CN1229331C
CN1229331C CNB028060253A CN02806025A CN1229331C CN 1229331 C CN1229331 C CN 1229331C CN B028060253 A CNB028060253 A CN B028060253A CN 02806025 A CN02806025 A CN 02806025A CN 1229331 C CN1229331 C CN 1229331C
Authority
CN
China
Prior art keywords
methyl
phenyl
oxy
aminopropane
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB028060253A
Other languages
English (en)
Chinese (zh)
Other versions
CN1494526A (zh
Inventor
E·L·马蒂尤滋
J·－M·索尔
W·J·惠勒
D·T·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1229331(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1494526A publication Critical patent/CN1494526A/zh
Application granted granted Critical
Publication of CN1229331C publication Critical patent/CN1229331C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNB028060253A 2001-03-06 2002-02-20 一元胺吸收的抑制剂 Ceased CN1229331C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
US60/273,730 2001-03-06

Publications (2)

Publication Number Publication Date
CN1494526A CN1494526A (zh) 2004-05-05
CN1229331C true CN1229331C (zh) 2005-11-30

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028060253A Ceased CN1229331C (zh) 2001-03-06 2002-02-20 一元胺吸收的抑制剂

Country Status (35)

Country Link
US (2) US20040082666A1 (enExample)
EP (1) EP1379492B1 (enExample)
JP (1) JP2004525912A (enExample)
KR (1) KR20030092012A (enExample)
CN (1) CN1229331C (enExample)
AP (1) AP2003002855A0 (enExample)
AT (2) ATE396170T1 (enExample)
AU (1) AU2002245385B2 (enExample)
BR (1) BR0207716A (enExample)
CA (1) CA2440161A1 (enExample)
CH (1) CH695982A5 (enExample)
CZ (1) CZ20032380A3 (enExample)
DE (1) DE60226715D1 (enExample)
DK (1) DK200301267A (enExample)
EA (1) EA005768B1 (enExample)
EC (1) ECSP034760A (enExample)
EE (1) EE200300419A (enExample)
ES (2) ES2305221T3 (enExample)
FI (1) FI20031191A7 (enExample)
GB (1) GB2389851B (enExample)
HR (1) HRP20030710A2 (enExample)
HU (1) HUP0303341A3 (enExample)
IL (1) IL157779A0 (enExample)
LT (1) LT5143B (enExample)
LU (1) LU91038B1 (enExample)
LV (1) LV13119B (enExample)
NO (1) NO20033921L (enExample)
NZ (1) NZ527431A (enExample)
OA (1) OA12494A (enExample)
PL (1) PL363840A1 (enExample)
SE (1) SE526598C2 (enExample)
SK (1) SK10632003A3 (enExample)
TR (1) TR200705146T1 (enExample)
WO (1) WO2002070457A1 (enExample)
ZA (1) ZA200306882B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030092012A (ko) * 2001-03-06 2003-12-03 일라이 릴리 앤드 캄파니 모노아민 흡수 억제제
EP1660065A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
DE602004014823D1 (de) * 2003-12-12 2008-08-14 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
US20210401790A1 (en) * 2018-10-31 2021-12-30 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA1327795C (en) * 1987-08-14 1994-03-15 Jules Freedman Antidepressants which are aryloxy inadanamines
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
AU3219800A (en) 1999-03-29 2000-10-16 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
JP2002541235A (ja) 1999-04-09 2002-12-03 イーライ・リリー・アンド・カンパニー ３−アリールオキシ−３−アリールプロピルアミン及びその中間体の製造方法
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
KR20030092012A (ko) * 2001-03-06 2003-12-03 일라이 릴리 앤드 캄파니 모노아민 흡수 억제제

Also Published As

Publication number Publication date
LV13119B (en) 2004-06-20
GB0323169D0 (en) 2003-11-05
ES2201942A1 (es) 2004-03-16
NO20033921D0 (no) 2003-09-04
ECSP034760A (es) 2003-10-28
US7384983B2 (en) 2008-06-10
FI20031191L (fi) 2003-08-25
GB2389851B (en) 2005-05-25
AT414238B (de) 2006-10-15
CH695982A5 (de) 2006-11-15
AP2003002855A0 (en) 2003-08-20
CZ20032380A3 (en) 2004-03-17
NZ527431A (en) 2005-05-27
EA005768B1 (ru) 2005-06-30
ES2305221T3 (es) 2008-11-01
NO20033921L (no) 2003-11-05
LU91038B1 (fr) 2003-09-11
WO2002070457A1 (en) 2002-09-12
BR0207716A (pt) 2004-03-23
GB2389851A (en) 2003-12-24
EP1379492A1 (en) 2004-01-14
HUP0303341A2 (hu) 2004-01-28
AU2002245385B2 (en) 2007-01-18
LT2003075A (en) 2004-03-25
KR20030092012A (ko) 2003-12-03
ATE396170T1 (de) 2008-06-15
TR200705146T1 (tr) 2008-02-21
HRP20030710A2 (en) 2004-08-31
ATA90422002A (de) 2006-01-15
US20040082666A1 (en) 2004-04-29
SE0302361L (sv) 2003-09-03
SE0302361D0 (sv) 2003-09-03
ES2201942B2 (es) 2004-12-16
EA200300978A1 (ru) 2004-02-26
FI20031191A7 (fi) 2003-08-25
WO2002070457A8 (en) 2004-06-03
IL157779A0 (en) 2004-03-28
ZA200306882B (en) 2004-12-03
PL363840A1 (pl) 2004-11-29
SE526598C2 (sv) 2005-10-18
OA12494A (en) 2006-05-24
JP2004525912A (ja) 2004-08-26
SK10632003A3 (sk) 2004-06-08
DE60226715D1 (de) 2008-07-03
EE200300419A (et) 2004-02-16
US20050209341A1 (en) 2005-09-22
CN1494526A (zh) 2004-05-05
LT5143B (lt) 2004-06-25
CA2440161A1 (en) 2002-09-12
EP1379492B1 (en) 2008-05-21
HUP0303341A3 (en) 2007-03-28
DK200301267A (da) 2003-11-06

Similar Documents

Publication Publication Date Title
TWI436762B (zh) 二環性γ－胺基酸衍生物
EP0288188B1 (en) 1-phenyl-3-naphthalenyloxy-propanamines
AU2023229513A1 (en) Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
ES2315425T3 (es) Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos.
CN1229331C (zh) 一元胺吸收的抑制剂
US9499476B2 (en) Acetamide stereoisomer
US20050020541A1 (en) Silicon compounds
AU2002245385A1 (en) Inhibitor of monoamine uptake
JPH02235A (ja) セロトニンおよびノルエピネフリン摂取阻害剤
KR20100065303A (ko) 카바메이트 입체이성체
AU2007201684A1 (en) Inhibitor of monoamine uptake
WO2001083453A1 (en) Novel substituted tricyclic compounds
UA80190C2 (en) Sustituted indoline and indole derivatives
JPWO2001083453A1 (ja) 置換基を有する新規３環性化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
C35 Partial or whole invalidation of patent or utility model
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20100429

Decision number of declaring invalidation: 14762

Granted publication date: 20051130